CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 (⁶⁴Cu) production. Together, the developments reflect the company’s focus on helping institutions build the production capabilities behind their molecular imaging programs—from establishing local PET radioisotope production to supporting research into emerging radiophar
